JPH06507182A - Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物 - Google Patents

Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物

Info

Publication number
JPH06507182A
JPH06507182A JP5512992A JP51299293A JPH06507182A JP H06507182 A JPH06507182 A JP H06507182A JP 5512992 A JP5512992 A JP 5512992A JP 51299293 A JP51299293 A JP 51299293A JP H06507182 A JPH06507182 A JP H06507182A
Authority
JP
Japan
Prior art keywords
alkyl
compound
substituted
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5512992A
Other languages
English (en)
Japanese (ja)
Inventor
フロン、ロイ
ガルシア、ジョルジュ
ニサト、ディノ
ルクス、リシャール
セラデイユーレガール、クロディーヌ
バレッテ、ゲラール
ワグノン、ジャン
Original Assignee
エルフ・サノフィ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルフ・サノフィ filed Critical エルフ・サノフィ
Publication of JPH06507182A publication Critical patent/JPH06507182A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C07D209/92—Naphthostyrils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP5512992A 1992-01-30 1993-01-28 Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物 Pending JPH06507182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR92/01034 1992-01-30
FR9201034A FR2686878B1 (fr) 1992-01-30 1992-01-30 Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
PCT/FR1993/000093 WO1993015051A1 (fr) 1992-01-30 1993-01-28 Derives du n-sulfonyl-2-oxoindole ayant une affinite pour les recepteurs de la vasopressine et/ou de l'ocytocine

Publications (1)

Publication Number Publication Date
JPH06507182A true JPH06507182A (ja) 1994-08-11

Family

ID=9426168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5512992A Pending JPH06507182A (ja) 1992-01-30 1993-01-28 Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物

Country Status (20)

Country Link
EP (1) EP0581939B1 (https=)
JP (1) JPH06507182A (https=)
AT (1) ATE180773T1 (https=)
AU (1) AU662960B2 (https=)
BR (1) BR9303993A (https=)
CA (1) CA2107348A1 (https=)
CZ (1) CZ203793A3 (https=)
DE (1) DE69325130D1 (https=)
FI (2) FI934274L (https=)
FR (1) FR2686878B1 (https=)
HU (1) HUT68642A (https=)
IL (1) IL104559A0 (https=)
MX (1) MX9300498A (https=)
NO (1) NO180538C (https=)
NZ (1) NZ249158A (https=)
RU (1) RU2135469C1 (https=)
SK (1) SK105393A3 (https=)
TW (1) TW239126B (https=)
WO (1) WO1993015051A1 (https=)
ZA (1) ZA93649B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080574A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
JP2008534460A (ja) * 2005-03-24 2008-08-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、それを含む医薬品およびそれの使用
JP2010504351A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬として使用されるスピロベンズアゼピン類
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
JP2010512374A (ja) * 2006-12-12 2010-04-22 サノフイ−アベンテイス ５−アルキルオキシ−インドリン−２−オン誘導体、これらの調製およびｖ２バソプレシン受容体の選択的リガンドとしての治療におけるこれらの応用
JP2011507931A (ja) * 2007-12-27 2011-03-10 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体およびこれらのバソプレシン依存性疾病の治療用の使用
JP2011518213A (ja) * 2008-04-21 2011-06-23 サノフイ−アベンテイス １，３−ジヒドロ−２Ｈ−ピロロ［３，２−ｂ］ピリジン−２−オン誘導体、この調製、およびこの治療用途

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2722190B1 (fr) * 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FR2740136B1 (fr) * 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
HUP0203548A3 (en) 1999-07-21 2003-04-28 Astrazeneca Ab New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
DE10222034A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
DK1523486T3 (da) * 2002-06-21 2008-03-03 Suven Life Sciences Ltd Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet
RU2259999C2 (ru) * 2003-08-26 2005-09-10 ООО "Исследовательский институт химического разнообразия" 1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CA2593044A1 (en) * 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
CA2602194A1 (en) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
DE102005015957A1 (de) * 2005-03-31 2006-10-05 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
EP1957480A1 (de) 2005-12-02 2008-08-20 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102006040915A1 (de) 2006-08-26 2008-03-20 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US8119676B2 (en) 2006-08-26 2012-02-21 Abbott GmbH & Co. HG Substituted benzimidazolone derivatives, medicaments comprising them and their use
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CA2707671C (en) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
CA2707669C (en) 2007-12-07 2016-07-05 Wilfried Braje 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
FR2927625B1 (fr) * 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
RU2743747C2 (ru) * 2016-01-20 2021-02-25 Кемосентрикс, Инк. 2-оксиндольные соединения
CN114702448A (zh) * 2021-09-30 2022-07-05 西南大学 环烯烃的三氟甲基化串联环化螺环化合物的合成方法
CN119019312B (zh) * 2024-10-24 2025-01-28 苏州宜联生物医药有限公司 一种吲哚-2-酮衍生物、其抗体药物偶联物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540057A (en) 1947-07-02 1951-01-30 Gen Aniline & Film Corp Aromatic and heterocyclic diazosulfones
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
DK167393B1 (da) 1985-12-30 1993-10-25 Roussel Uclaf 1-sulfonyl-2-oxo-pyrrolidinderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf
US4863437A (en) * 1986-03-20 1989-09-05 Clarke Ellis W Means for fluid administration
US4803217A (en) * 1986-12-24 1989-02-07 Merck & Co., Inc. Hapalindolinone compounds as vassopressin antagonists
EP0303418A3 (en) * 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
KR930011300B1 (ko) * 1989-07-25 1993-11-29 다이호오 야꾸힌 고오교오 가부시끼가이샤 옥시인돌유도체

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080574A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
US8030499B2 (en) 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
JP5125501B2 (ja) * 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物
JP2008534460A (ja) * 2005-03-24 2008-08-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、それを含む医薬品およびそれの使用
JP2010504351A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬として使用されるスピロベンズアゼピン類
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
JP2010512374A (ja) * 2006-12-12 2010-04-22 サノフイ−アベンテイス ５−アルキルオキシ−インドリン−２−オン誘導体、これらの調製およびｖ２バソプレシン受容体の選択的リガンドとしての治療におけるこれらの応用
JP2011507931A (ja) * 2007-12-27 2011-03-10 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体およびこれらのバソプレシン依存性疾病の治療用の使用
JP2011518213A (ja) * 2008-04-21 2011-06-23 サノフイ−アベンテイス １，３−ジヒドロ−２Ｈ−ピロロ［３，２−ｂ］ピリジン−２−オン誘導体、この調製、およびこの治療用途

Also Published As

Publication number Publication date
TW239126B (https=) 1995-01-21
IL104559A0 (en) 1993-05-13
FI980341A7 (fi) 1998-02-13
CZ203793A3 (en) 1994-04-13
CA2107348A1 (en) 1993-07-31
FI980341A0 (fi) 1998-02-13
AU3504393A (en) 1993-09-01
WO1993015051A1 (fr) 1993-08-05
NO180538C (no) 1997-05-07
MX9300498A (es) 1994-07-29
SK105393A3 (en) 1994-08-10
FI934274A7 (fi) 1993-09-29
EP0581939B1 (fr) 1999-06-02
NO933482D0 (no) 1993-09-29
FR2686878A1 (fr) 1993-08-06
RU2135469C1 (ru) 1999-08-27
FR2686878B1 (fr) 1995-06-30
DE69325130D1 (de) 1999-07-08
FI980341L (fi) 1998-02-13
BR9303993A (pt) 1994-08-02
HU9302762D0 (en) 1993-12-28
AU662960B2 (en) 1995-09-21
NZ249158A (en) 1996-02-27
EP0581939A1 (fr) 1994-02-09
FI934274A0 (fi) 1993-09-29
HUT68642A (en) 1995-07-28
FI934274L (fi) 1993-09-29
ATE180773T1 (de) 1999-06-15
NO180538B (no) 1997-01-27
NO933482L (no) 1993-11-29
ZA93649B (en) 1993-09-02

Similar Documents

Publication Publication Date Title
JPH06507182A (ja) Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物
EP0950047B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0873309B1 (fr) Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
US5585394A (en) 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
EP0687251B1 (fr) Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine
RU2141476C1 (ru) Производные 1-бензолсульфонил-1,3-дигидро-индол-2-она, способ их получения и содержащие их фармацевтические композиции
SK404091A3 (en) Indole derivatives, method of production and pharmaceutical agents containing them
US5661169A (en) 1-benzyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation and the pharmaceutical compositions containing them
US4351770A (en) Preparation of N(2-pyrrolidinylmethyl)2-methoxy-5-benzenesulfonamidobenzamides
US4180581A (en) N-9,10-dihydrolysergyl-m-aminobenzoic acid amide derivative
JP3898219B2 (ja) フエニルインドール化合物
HK1016596B (en) 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands